Brilinta

Phase 3Small molecule

AstraZeneca

Brilinta is one of 138 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

137

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery DiseaseUnknown

Acute Coronary SyndromeUnknown

Sickle Cell DiseaseActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Coronary Artery DiseasePreclinical

Unknown

Acute Coronary SyndromePreclinical

Unknown

Sickle Cell DiseasePhase 3

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Brilinta

AstraZeneca

Phase 3

3 2

Uloric

Takeda

Preclinical

3 3

Lorelco

Sanofi

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Glucotrol

Pfizer

Preclinical

1 6

Vemlidy

Gilead

Preclinical

1 7

Flomax

Sanofi

Preclinical

—8

Miochol

BBausch Health Americas, Inc.

Preclinical

2 9

Sodium Valproate

AstraZeneca

Preclinical

4 10

Tradjenta

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adult1 trial

Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition

Completed·UUniversity of Karachi·Phase 1·NCT04941196·30 enrolled

Sickle Cell Disease1 trial

Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 3·NCT04293172

GIST1 trial

Use of Ticagrelor in Korean ACS Patients: The BRILIANT KOREA Registry

Unknown status·SSeoul National University Hospital··NCT02521038·2,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Brilinta. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Brilinta compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Brilinta. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Brilinta

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adult1 trial

Sickle Cell Disease1 trial

GIST1 trial

References

Drug Info

Quick Facts

Related News